Skip to content
1887

Access Microbiology open research platform logo Access Microbiology

Volume 7, Issue 12

Analysis of a simple disk diffusion method to evaluate ceftazidime–avibactam/aztreonam combination synergism against New Delhi metallo-beta-lactamase-producing clinical isolates Open Access

Abstract

The rise of multidrug-resistant and has diminished the reliability of conventional antibiotics for treating Multidrug Resistant (MDR) infections. The combination of ceftazidime–avibactam with aztreonam has demonstrated synergism against multidrug-resistant organisms, notably metallo-beta-lactamase-producing strains. Treatment with the ceftazidime–avibactam/aztreonam combination may provide clinical benefits for patients with multidrug-resistant bacterial infections. The present study aimed to detect genes encoding carbapenem resistance in clinical strains and to determine the efficacy of ceftazidime–avibactam/aztreonam against carbapenemase co-producers. A cross-sectional research study was conducted on 62 carbapenem-resistant clinical isolates collected from November 2022 to February 2024. Ceftazidime–avibactam/aztreonam synergy against 55 carbapenemase producers [New Delhi metallo-beta-lactamase (NDM), imipenem-hydrolysing metallo-beta-lactamase (IMP), Verona Integron-encoded metallo-beta-lactamase (VIM) and oxacillinase-48 (OXA-48)] was determined using the disc diffusion method. Data analysis was performed by chi-square test. Ceftazidime–avibactam/aztreonam synergy was identified against 25 (64.1%) out of 39 isolates exhibiting the NDM gene, seven (77.8%) out of nine isolates that were co-producers of NDM and OXA-48 genes, two (50%) out of four isolates co-producing NDM and VIM carbapenemase genes and a single isolate (33.3%) out of three isolates with NDM, VIM and OXA-48 genes. A wide zone of 3–23 mm diameter was observed for and 6–7 mm for with ceftazidime–avibactam/aztreonam in relative to ceftazidime–avibactam and aztreonam discs when tested alone. More than 30% of isolates showed a statistically significant difference in zone diameter for the ceftazidime–avibactam/aztreonam combination (<0.05), when compared with the zone size for ceftazidime–avibactam and aztreonam discs when tested alone. The present study showed the effectiveness of the ceftazidime–avibactam/aztreonam combination against 63.6% of carbapenem-resistant isolates studied. The disc diffusion method requires less technical expertise, and the test result aids in identifying true clinical synergy by observing the widening of the zone diameter that exceeds the aztreonam susceptibility breakpoint.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): ceftazidime–avibactam/aztreonam , Enterobacterales , in vitro synergy , multiple carbapenemase producer , Pseudomonas aeruginosa and synergic combination
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.001049.v4
2025-12-15
2026-02-14

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/acmi/7/12/acmi001049.v4.html?itemId=/content/journal/acmi/10.1099/acmi.0.001049.v4&mimeType=html&fmt=ahah

References

  1. Haji SH, Aka STH, Ali FA. Prevalence and characterisation of carbapenemase encoding genes in multidrug-resistant gram-negative bacilli. PLoS One 2021; 16:e0259005 [View Article] [PubMed]
     [Google Scholar]
  2. Sahin K, Tekin A, Ozdas S, Akin D, Yapislar H et al. Evaluation of carbapenem resistance using phenotypic and genotypic techniques in Enterobacteriaceae isolates. Ann Clin Microbiol Antimicrob 2015; 14:44 [View Article] [PubMed]
     [Google Scholar]
  3. Kamel NA, Tohamy ST, Yahia IS, Aboshanab KM. Insights on the performance of phenotypic tests versus genotypic tests for the detection of carbapenemase-producing Gram-negative bacilli in resource-limited settings. BMC Microbiol 2022; 22:248 [View Article] [PubMed]
     [Google Scholar]
  4. Urmi UL, Nahar S, Rana M, Sultana F, Jahan N et al. Genotypic to phenotypic resistance discrepancies identified involving β-lactamase genes, blakpc, blaimp, blandm-1 and blavim in uropathogenic klebsiella pneumoniae. Infect Drug Resist 2020; 13:2863–2875 [View Article]
     [Google Scholar]
  5. Mikhail S, Singh NB, Kebriaei R, Rice SA, Stamper KC et al. Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2019; 63:e00779-19 [View Article] [PubMed]
     [Google Scholar]
  6. Matesanz M, Mensa J. Ceftazidime-avibactam. Rev Esp Quimioter 2021; 34 Suppl 1:38–40 [View Article] [PubMed]
     [Google Scholar]
  7. Cismaru IM, Văcăroiu MC, Soium E, Holban T, Radu AM et al. Synergistic combination of aztreonam and ceftazidime-avibactam-A promising defense strategy against OXA-48 + NDM Klebsiella pneumoniae in Romania. Antibiotics (Basel) 2024; 13:550 [View Article] [PubMed]
     [Google Scholar]
  8. Bakthavatchalam YD, Walia K, Veeraraghavan B. Susceptibility testing for aztreonam plus ceftazidime/avibactam combination: a general guidance for clinical microbiology laboratories in India. Indian J Med Microbiol 2022; 40:3–6 [View Article] [PubMed]
     [Google Scholar]
  9. Song P, Xu J, Jiang L, Zhang Q, Liu C. Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against Enterobacterales isolates. Microbiol Spectr 2024; 12:e0095324 [View Article] [PubMed]
     [Google Scholar]
  10. Khattab S, Askar AM, Abdellatif HAA, Othman AAA, Rayan AH et al. Synergistic combination of ceftazidime and avibactam with aztreonam against MDR Klebsiella pneumoniae in ICU patients. Sci Rep 2025; 15:5102 [View Article] [PubMed]
     [Google Scholar]
  11. Khan S, Das A, Vashisth D, Mishra A, Vidyarthi AJ et al. Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales. PLoS One 2021; 19:e0303753 [View Article]
     [Google Scholar]
  12. Clinical and Laboratory Standards Institute [CLSI] Performance Standards for Antimicrobial Susceptibility Testing, Approved Standard M100S30, 31st ed. Wayne, PA: CLSI; 2021
     [Google Scholar]
  13. Khan A, Erickson SG, Pettaway C, Arias CA, Miller WR et al. Evaluation of susceptibility testing methods for aztreonam and ceftazidime-avibactam combination therapy on extensively drug-resistant gram-negative organisms. Antimicrob Agents Chemother 2021; 65:e0084621 [View Article] [PubMed]
     [Google Scholar]
  14. Tan X, Kim HS, Baugh K, Huang Y, Kadiyala N et al. Therapeutic options for metallo-β-lactamase-producing Enterobacterales. IDR 2021; Volume 14:125–142 [View Article]
     [Google Scholar]
  15. Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L. The Revival of aztreonam in combination with avibactam against metallo-β-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases. Antibiotics (Basel) 2021; 10:1012 [View Article] [PubMed]
     [Google Scholar]
  16. Rai M, Basu S, Kambli P, Drego L, Patel P et al. Unleashing the potent synergy of ceftazidime-avibactam and aztreonam against metallo-beta-lactamase producing Enterobacterales in the battle against antibiotic resistance. An in vitro study. Indian J Med Microbiol 2025; 54:100819 [View Article] [PubMed]
     [Google Scholar]
  17. Prayag PS, Panchakshari S, Soman RN, Dhupad S, Patwardhan SA et al. Ceftazidime-avibactam with or without aztreonam vs polymyxin-based combination therapy for carbapenem-resistant Enterobacteriaceae: a retrospective analysis. Indian J Crit Care Med 2023; 27:444–450 [View Article]
     [Google Scholar]
  18. Klein N, Jantsch J, Simon M, Rödel J, Becker SL et al. In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains. Infection 2025; 53:1061–1068 [View Article] [PubMed]
     [Google Scholar]
  19. Adam MA, Elhag WI. Prevalence of metallo-β-lactamase acquired genes among carbapenems susceptible and resistant Gram-negative clinical isolates using multiplex PCR, Khartoum hospitals, Khartoum Sudan. BMC Infect Dis 2018; 18:668 [View Article] [PubMed]
     [Google Scholar]
  20. Mohamed A, Daef E, Nafie A, Shaban L, Ibrahim M. Characteristics of carbapenem-resistant gram-negative bacilli in patients with ventilator-associated pneumonia. Antibiotics 2021; 10:1325 [View Article] [PubMed]
     [Google Scholar]
  21. Sahu C, Pal S, Patel SS, Singh S, Gurjar M et al. Phenotypic synergy testing of ceftazidime-avibactam with aztreonam in a university hospital having high number of metallobetalactamase producing bacteria. Infect Dis 2020; 52:801–807 [View Article] [PubMed]
     [Google Scholar]
  22. Sreenivasan P, Sharma B, Kaur S, Rana S, Biswal M et al. In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era. J Antibiot 2022; 75:454–462 [View Article] [PubMed]
     [Google Scholar]
  23. Lima K de O, de Lima AV, Rocha DA da C, Sampaio SCF, Cappellano P et al. A simple disk pre-diffusion test to predict in vitro aztreonam/avibactam activity against NDM-producing Klebsiella pneumoniae complex. J Glob Antimicrob Resist 2022; 28:49–52 [View Article] [PubMed]
     [Google Scholar]
  24. ICMR Guidance on diagnosis & management of carbapenem-resistant gram-negative infections. Indian Council of Medical Research; 2022 https://www.icmr.gov.in/icmrobject/custom_data/pdf/resource-guidelines/Diagnosis_and_management_of_CROs.pdf accessed 24 July 2023
  25. Biagi M, Wu T, Lee M, Patel S, Butler D et al. Searching for the optimal treatment for metallo- and serine-β-lactamase producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam. Antimicrob Agents Chemother 2019; 63:e01426-19 [View Article] [PubMed]
     [Google Scholar]
  26. Romanelli F, De Robertis A, Carone G, Dalfino L, Stufano M et al. In vitro activity of ceftazidime/avibactam alone and in combination with fosfomycin and carbapenems against KPC-producing Klebsiella Pneumoniae. New Microbiol 2020; 43:136–138 [PubMed]
     [Google Scholar]
  27. Sempere A, Viñado B, Los-Arcos I, Campany D, Larrosa N et al. Ceftazidime-avibactam plus aztreonam for the treatment of infections by VIM-Type-Producing Gram-Negative Bacteria. Antimicrob Agents Chemother 2022; 66:e0075122 [View Article] [PubMed]
     [Google Scholar]
  28. Lu G, Tang H, Xia Z, Yang W, Xu H et al. In vitro and in vivo antimicrobial activities of ceftazidime/avibactam alone or in combination with aztreonam against carbapenem-resistant Enterobacterales. Infect Drug Resist 2022; 15:7107–7116 [View Article] [PubMed]
     [Google Scholar]
  29. Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-β-lactamase-producing Enterobacterales. Clin Infect Dis 2021; 72:1871–1878 [View Article] [PubMed]
     [Google Scholar]
  30. Mantzarlis K, Manoulakas E, Parisi K, Sdroulia E, Zapaniotis N et al. Meropenem plus ertapenem and ceftazidime-avibactam plus aztreonam for the treatment of ventilator associated pneumonia caused by pan-Drug Resistant Klebsiella pneumonia. Antibiotics (Basel) 2024; 13:141 [View Article] [PubMed]
     [Google Scholar]
  31. Shah A, Nagvekar V, Unadkat VP, Chavan A, Kohli R et al. Clinical outcome of patients on ceftazidime–avibactam and combination therapy in carbapenem-resistant Enterobacteriaceae. Indian J Crit Care Med 2021; 25:780–784 [View Article]
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.001049.v4
Loading
Analysis of a simple disk diffusion method to evaluate ceftazidime–avibactam/aztreonam combination synergism against New Delhi metallo-beta-lactamase-producing clinical isolates
Access Microbiology 7, 001049.v4 (2025); https://doi.org/10.1099/acmi.0.001049.v4
/content/journal/acmi/10.1099/acmi.0.001049.v4
/content/journal/acmi/10.1099/acmi.0.001049.v4
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error